Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies

Profusa (Nasdaq: PFSA) entered a know-how agreement with Mayo Clinic on Feb. 12, 2026 to investigate high-impact clinical applications of its Lumee™ continuous tissue oxygen monitoring technology.

Rhea-AI Summary

Profusa (Nasdaq: PFSA) entered a know-how agreement with Mayo Clinic on Feb. 12, 2026 to investigate high-impact clinical applications of its Lumee™ continuous tissue oxygen monitoring technology.

The collaboration targets potential U.S. commercialization for critical limb ischemia and new tethered products across cardiovascular, renal, multi-organ, and orthopedic indications. Profusa cites over $100 million invested in Lumee development; Mayo Clinic holds a financial interest and will use any revenue to support its mission.

Positive

• Signed know-how agreement with Mayo Clinic (Feb. 12, 2026)
• Targeting U.S. commercialization of Lumee for critical limb ischemia
• $100 million+ invested in Lumee development to date
• Multiple clinical indications targeted: cardiovascular, renal, multi-organ, orthopedic

Negative

• No regulatory approval yet for new Lumee indications
• Commercial outcome uncertain despite collaboration and investment
• Mayo Clinic financial interest may create perceived conflicts

Argus Feb 13 session

-33.44% close to close Open Argus

Details

News Market Reaction – PFSA

On Feb 13, the first trading day after this news, PFSA closed 33.44% below the previous close.

Data tracked by StockTitan Argus for the Feb 13 session.

Market Context

On Feb 13, the first trading day after this news, the stock closed 33.4% below the previous close. A...

Analysis

On Feb 13, the first trading day after this news, the stock closed 33.4% below the previous close. A negative reaction despite this collaboration would fit a pattern where previous positive clinical and commercial milestones sometimes saw muted or adverse price responses, as with the Lumee distribution and trial updates. With shares already well below the 200-day MA of $24.46 and close to the $2.85 52-week low, sentiment has been fragile. Any pullback would underscore investor focus on funding needs, regulatory timelines, and the pace of real-world commercial uptake.

Key Figures

Lumee investment: over $100 million

Lumee investment

over $100 million

Total investment in Lumee technology over more than a decade

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Reverse stock split

   24h Move

   -36.4%

   1-for-75 reverse split reducing outstanding shares; shares fell sharply.

2. Jan 29

   Clinical data update

   24h Move

   -3.4%

   Positive US pilot study results for Lumee oxygen sensor and revenue outlook.

3. Jan 16

   Product launch

   24h Move

   +4.1%

   Launch of Lumee tissue oxygen Healthcare Research offering and RUO kits.

4. Jan 08

   Customer addition

   24h Move

   +0.1%

   Leading Greek vascular surgeon adopts Lumee Oxygen for practice and studies.

5. Dec 31

   Distribution deal

   24h Move

   -14.0%

   French Lumee Oxygen distributor MedSell and long-term revenue targets announced.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

continuous tissue oxygen monitoring, critical limb ischemia, postoperative perfusion monitoring, biochemistry

4 terms

continuous tissue oxygen monitoring medical

"Lumee™ wearable continuous tissue oxygen monitoring product"

Continuous tissue oxygen monitoring is a medical technology that uses sensors to measure oxygen levels in body tissues constantly over time, acting like a fuel gauge that shows whether organs and wounds are getting enough oxygen. Investors care because steady, real-time readings can improve patient outcomes, shorten hospital stays and drive demand, which affects a product’s adoption, regulatory approval prospects, and potential market size.

critical limb ischemia medical

"Lumee oxygen sensing and tissue monitoring technology for critical limb ischemia in the U.S."

Critical limb ischemia is a severe, long-lasting reduction of blood flow to an arm or leg that causes constant pain, slow-healing wounds, or tissue loss and often risks amputation if not treated. Think of it like a garden hose nearly clogged so plants downstream start dying; restoring flow usually requires medical procedures, long-term care, and expensive devices or drugs, so its prevalence and treatment outcomes directly affect healthcare costs, device sales and drug market opportunities for investors.

postoperative perfusion monitoring medical

"where intra-organ postoperative perfusion monitoring has potential to improve clinical outcomes."

Postoperative perfusion monitoring is the ongoing measurement of blood flow and oxygen delivery to tissues after surgery, often using sensors or imaging to spot areas that are not receiving enough circulation. Like checking water pressure after fixing a pipe, it helps clinicians detect complications early, reduce the chance of reoperation, shorten hospital stays and improve recovery—factors that affect costs, device demand and reimbursement outcomes important to investors.

biochemistry medical

"enable the continuous monitoring of an individual’s biochemistry"

The study of the chemical processes and molecules inside living organisms — how proteins, genes, enzymes and other small molecules interact and drive life’s functions. Investors care because biochemistry is the foundation of drug discovery, diagnostics, and biotech products; understanding it helps explain how a therapy works, the technical risk of development, potential regulatory hurdles, and whether a company’s science could translate into a profitable product. Think of it as the recipe and machinery behind a biological product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product

Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications

BERKELEY, Calif, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual’s biochemistry, has entered into a know-how agreement with Mayo Clinic.  The collaboration entails investigation of high impact clinical applications of Profusa’s oxygen monitoring technologies for new product development and commercialization.  Potential target indications include cardiovascular, renal, multi-organ, and orthopedic applications, among others, where intra-organ postoperative perfusion monitoring has potential to improve clinical outcomes. The collaboration also supports Profusa’s potential commercialization of Lumee oxygen sensing and tissue monitoring technology for critical limb ischemia in the U.S.

Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic, Rochester, Minn., said, “Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure. Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including the ability to monitor beyond subcutaneous tissue.”

“Following more than a decade of development and over $100 million in investment, our Lumee technology enables continuous, real-time measurement of tissue oxygen directly within the body, which we believe to be a first-of-its-kind, disruptive biochemistry monitoring platform. In addition, we are committed to continue to harness our platform technology for innovative solutions that seek to both address large unmet clinical needs and reduce costs for healthcare systems through earlier detection and improved disease management.  We look forward to collaborating with Mayo Clinic for the U.S. commercialization of Lumee for critical limb ischemia, and developing products to address new indications to expand our oxygen tissue monitoring technology’s market and therapeutic reach.”, said Ben Hwang, Ph.D., Profusa’s Chairman and CEO.

Mayo Clinic has a financial interest in the technology referenced in this press release.  Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts
Investor and Media Contacts
email:  info@coreir.com
phone:  1 (212) 655-0924

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Profusa announce about the Mayo Clinic collaboration on Feb. 12, 2026 (PFSA)?

Profusa announced a know-how agreement with Mayo Clinic to investigate high-impact clinical uses for Lumee tissue oxygen monitoring. According to Profusa, the collaboration aims to accelerate product development, regulatory pathways, and potential U.S. commercialization for critical limb ischemia and other indications.

Will Profusa commercialize Lumee for critical limb ischemia in the U.S. (PFSA)?

Profusa aims to commercialize Lumee in the U.S. for critical limb ischemia following collaboration with Mayo Clinic. According to Profusa, the partnership supports potential U.S. commercialization while investigating clinical utility across relevant surgical and vascular care settings.

What clinical indications is Profusa targeting with Lumee under the Mayo Clinic agreement (PFSA)?

Profusa is targeting cardiovascular, renal, multi-organ, orthopedic, and postoperative perfusion monitoring applications. According to Profusa, these indications focus on intra-organ postoperative perfusion where continuous tissue oxygen data may improve clinical outcomes and wound healing.

How much has Profusa invested in Lumee development before the Mayo Clinic deal (PFSA)?

Profusa reports more than $100 million invested in Lumee development over a decade. According to Profusa, that investment supported the platform’s development toward continuous, real-time in-body tissue oxygen measurement and commercial-stage activities.

Does Mayo Clinic have any financial interest in Profusa’s Lumee technology (PFSA)?

Yes, Mayo Clinic disclosed a financial interest in the referenced technology and will use any revenue to support its mission. According to Profusa, Mayo Clinic’s interest is disclosed as part of the collaboration and revenue use policy.